Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
BLENREP dosing regimen
BLENREP dosing & administration
BLENREP offers an off-the-shelf B-cell maturation antigen (BCMA)- targeting monotherapy with a short infusion time for patients with triple-class refractory multiple myeloma
For GB healthcare professionals only.*
Table of contents
The recommended dose of BLENREP is:1
Treatment should be continued until disease progression or unacceptable toxicity.1
Learn more about BLENREP side effects
5% (n=5/95) of patients discontinued due to eye-related side effects2
Adapted from BLENREP SmPC. Please see the SmPC for guidance on dosing and dose delays.
BVCA, best-corrected visual acuity.
*The severity category is defined by the most severely affected eye as both eyes may not be affected to the same degree.1
†An eye care professional can be an ophthalmologist or optometrist.
Mild superficial keratopathy is documented worsening from baseline, with or without symptoms.1
Moderate superficial keratopathy is with or without patchy microcyst-like deposits, sub-epithelial haze (peripheral), or a new peripheral stromal opacity.1
Severe superficial keratopathy is with or without diffuse microcyst-like deposits involving the central cornea, sub-epithelial haze (central), or a new central stromal opacity.1
A corneal defect may lead to corneal ulcers. These should be managed promptly and as clinically indicated by an eye care professional.1
In the DREAMM-2 study at 13 months follow up, 88% of responses were sustained or deepened, despite prolonged dose delays3
Clinical outcomes in a post-hoc analysis of patients who had prolonged dose delays (in which ≥3 treatment cycles were missed) in the 13-month follow up, after initially responding to BLENREP 2.5mg/kg (n=16/31)*3
Adapted from Lonial S, et al. Cancer. 2021.
*Percentages do not add up to 100% due to rounding.
†Indicates patients with elevated paraproteins reported during the delays, though these elevated paraproteins did not meet progressive disease criteria.3
One patient developed progressive disease 6 weeks into delay and one patient developed progressive disease 3 weeks after delay.3
Dig deeper into BLENREP with our resources library
Find out more about what BLENREP can offer your patients
*BLENREP is not commercially available in Northern Ireland.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1
Abbreviations
AE, adverse event; BCMA, B cell maturation antigen; BCVA, best corrected visual acuity; SmPC, Summary of Product Characteristics.
References
- BLENREP Summary of Product Characteristics.
- Nooka S, et al. Presented at the 64th American Society of Hematology Annual Meeting and Exposition, New Orleans, USA, December 10-13, 2022. Poster 3246.
- Lonial S, et al. Cancer. 2021;127(22):4198–4212.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
February 2023 | PM-GB-BLM-WCNT-220006 (V2.0)
